0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications

Valeria Santini, MD; Hagop M. Kantarjian, MD; and Jean-Pierre Issa, MD
[+] Article and Author Information

From the University of Texas M.D. Anderson Cancer Center, Houston, Texas; and University of Florence, Florence, Italy.


Acknowledgment: The authors thank Maria E. Perez for assistance in preparing the manuscript.

Grant Support: Work in Dr. Issa's laboratory is supported by grants from the National Institutes of Health, The Leukemia and Lymphoma Society of America, and the American Cancer Society.

Requests for Single Reprints: Hagop M. Kantarjian, MD, M.D. Anderson Cancer Center, Leukemia Department, Box 61, 1515 Holcombe Boulevard, Houston, TX 77030.

Current Author Addresses: Dr. Santini: Department of Hematology, University of Florence, Viale Morgagni 85, Florence, Italy.

Drs. Kantarjian and Issa: M.D. Anderson Cancer Center, Leukemia Department, Box 61, 1515 Holcombe Boulevard, Houston, TX 77030.


Ann Intern Med. 2001;134(7):573-586. doi:10.7326/0003-4819-134-7-200104030-00011
Text Size: A A A

Methylation of DNA is a biochemical modification that can influence gene expression and is involved in inactivating one of the two X chromosomes in women. Evidence that has accumulated in the past 10 years suggests that cancer cells usurp this physiologic mechanism and use it to their benefit by inactivating tumor suppressor genes and related proteins. However, the primary structure of the affected proteins remains intact; reversal of abnormalities in DNA methylation may therefore restore the tumor-suppressive function of these genes and provide a novel approach to cancer therapy. Two demethylating drugs, 5-azacytidine and 5-aza-deoxycytidine, are currently being tested in clinical trials, and several others are in preclinical development. In this article, the biological rationale for targeting aberrant methylation in cancer therapy is reviewed and completed phase I and II trials of this approach, some of which show promise for treatment of hematologic malignancies, are summarized.

Figures

Grahic Jump Location
Figure 1.
Structure of cytosine, 5-methylcytosine, and hypomethylating 5-methylcytidine analogues.
Grahic Jump Location
Grahic Jump Location
Figure 2.
The maintenance methylation process.Top.3Middle.3MtaseBottom.left5-Azaright

Some (but not all) cytosine-followed-by-guanosine (CpG) sites carry a methyl (CH ) group at the 5′ position of cytosine. Both strands of DNA are methylated (“fully methylated”). Immediately after DNA replication, the newly formed strand is unmethylated (no CH groups), resulting in hemimethylated double-stranded DNA, which rapidly attracts one of several methyltransferase ( ) enzymes. Through the action of methyltransferase enzymes, methyl groups are added symmetrically to hemimethylated CpG sites ( ), resulting in fully methylated DNA. In the presence of cytidine analogues ( ), methyltransferases are depleted, and the process of remethylation after replication is inhibited, leading to DNA that remains hemimethylated ( ). With subsequent rounds of replication in the absence of methyltransferases, DNA becomes progressively more demethylated, until most DNA molecules are completely unmethylated.

Grahic Jump Location
Grahic Jump Location
Figure 3.
Effects of methylation and histone deacetylation on gene expression and silencing.topblack boxesovalsarrows(leftmMBPbottomHDACrighttop

Initially ( ), genes ( ) are unmethylated, and the promoter region is occupied by transcription factors ( ) that direct production of messenger RNA ( ). De novo methylation, by itself, has a minimal effect on gene expression ). However, methylated DNA ( ) attracts methyl-binding proteins ( ), such as MeCp2 ( ). These methyl-binding proteins in turn attract a protein complex that contains histone deacetylases ( ). At this point, synthesis of messenger RNA synthesis is inhibited and no functional protein can be made from the gene. Through the action of methyl-binding proteins and histone deacetylases, the DNA structure changes to a compact, “condensed chromatin” configuration ( ), which results in permanent inhibition of messenger RNA and protein production (silencing). Hypomethylating agents can reverse this silenced state and restore messenger RNA and protein expression ( ). Histone deacetylase inhibitors act synergistically with hypomethylating agents to restore functional gene expression.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)